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In this study we evaluated, by means of the “cocaine rush visual analog scale,” the impact
of ropinirole on the expected rush induced by cocaine in a group of heroin addicts abusing
cocaine; the self-reported reaction to the rush blockade (if any) on cocaine consumption,
and the correlations between this self-reported reaction and individual, clinical, and thera-
peutic parameters. Nineteen cocaine abuser heroin-dependent patients entered the study.
Their experienced cocaine rushwas 61.31± 32.1% of themaximum effect previously expe-
rienced. Compared with their previous rush intensity 16 patients experienced signiﬁcantly
lower intensity, 3 the same intensity, and none a higher intensity. In particular, two patients
experienced a complete blockade of rush and reported a reduced use of cocaine. Four-
teen patients experienced a partial blockade of cocaine rush; of these, nine reported they
had reduced their use of cocaine. Ropinirole does diminish the subjective intensity of an
expected cocaine rush, so interfering with the dynamics of reward, while supporting its
possible use in the treatment of cocaine dependence.
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INTRODUCTION
To date, cocaine addiction is a poorly treatable disease that brings
with it major trouble in terms of mortality, morbidity, and social
life disruption (Dackis and O’Brien, 2001). In line with the par-
adigm of opiate addiction treatment, attempts have been made
to ascertain the therapeutic potential of a variety of medications
which have been tested for anti-craving and blocking properties
(McCance, 1997; Grabowski et al., 2000; Sofuoglu and Kosten,
2005). On biochemical grounds, the mesolimbic dopaminergic
pathway was regarded as the biological target in a majority of
trials, so that a large variety of dopaminergic agents have been
studied in cocaine addicts (Dackis and O’Brien, 2001; de Lima
et al., 2002; Kosten et al., 2002; Soares et al., 2003; Sofuoglu and
Kosten, 2005).
In rats, D2-selective dopamine antagonists increased cocaine
self-administration (Caine et al., 2002). Dopamine antagonism
alone, such as that provided by risperidone, or haloperidol and
ﬂuphenazine, does not seem to limit cocaine abuse, and may
exacerbate it in former cocaine abusers who are being treated for
psychoses (Ohuoha et al., 1997) or non-psychotic cocaine abusers
(Grabowski et al., 2000). Moreover, the blockade of cocaine-
induced subjective effects provided by D2-selective dopamine
antagonists is incomplete, even though it may render cocaine less
rewarding and more anxiogenic (Ohuoha et al., 1997). Disulﬁram
too has been employed in attempts to change the quality of cocaine
consumption from pleasant and rewarding to aversive with con-
trasting results (George et al., 2000; Petrakis et al., 2000;Mutschler
et al., 2009; Oliveto et al., 2011). The shifting of dopamine from
blocked D2 receptors to other subtypes, or the engagement of
dopamine excess on synaptic receptors may be responsible for
the aversive reactions related to D2 blockade. On the other hand,
partial antagonism may grant some beneﬁts, by combining an
anti-craving property with an at least partial cocaine blockade.
Unfortunately, current evidence does not support the clinical
use of dopamine agonists such as amantadine, bromocriptine, and
pergolide in the treatment of cocaine dependence (Soares et al.,
2003). Amantadine, however, does not seem to act at a receptorial
level and displayed no blockade property against cocaine-induced
subjective effects (Collins et al., 2003).
Aripiprazole (APZ) is an atypical antipsychotic, with pecu-
liar pharmacologic properties compared with the other second-
generation antipsychotics. APZ is the ﬁrst partial dopamine
agonist antipsychotic to reach clinical practice. The peculiar
partial-agonist activity at dopamine D2 receptors has stim-
ulated researchers to test APZ in the treatment of cocaine
abuse/addiction, but its efﬁcacy is still controversial (Janiri et al.,
2007; Cassano et al., 2009; Martinotti et al., 2009; Haney et al.,
2011; Meini et al., 2011).
Ropinirole is a D2-selective dopaminergic full agonist (Hoefer
et al., 2006) which does not show any signiﬁcant afﬁnity for the
D1 receptor subtype, while it binds weakly to the μ-opioid recep-
tor (Tulloch, 1997). It has proved useful and safe in the treatment
of Parkinson’s disease (Lam, 2000; Matheson and Spencer, 2000;
Jost, 2004) and Bipolar Depression (Perugi et al., 2001). A pilot
open-label trial of ropinirole for cocaine dependence has shown
promising results (Meini et al., 2008).
By applying this rationale, we formed the hypothesis that
ropinirole might display blocking properties against cocaine by
www.frontiersin.org August 2011 | Volume 2 | Article 50 | 1
Maremmani et al. Ropinirole and reinforcing effects of cocaine
acting as a competitive agonist. In this case it would be a can-
didate for the treatment of cocaine addiction. Our view would
be strengthened if ropinirole proved to be able to curtail the
reinforcement of cocaine’s subjective effects on humans.
The aims of the present study are: (1) to verify the impact of
ropinirole on the expected rush induced by cocaine in a group of
stabilized heroin addicts with concurrent abuse of cocaine, (2) to
evaluate the self-reported reaction to rush blockade, if any, on
cocaine consumption and, lastly, (3) to assess the correlations
between this self-reported reaction and individual, clinical and
therapeutic parameters.
MATERIALS AND METHODS
STUDY DESIGN
A naturalistic study was designed in order to assess, in a sample of
heroin-dependent patients with concurrent abuse of cocaine and
receiving treatment with opioid agonists, the impact of ropini-
role on the expected rush induced by cocaine. All the patients
included came from the PISA-methadone program. For the pro-
gram’s setting and characteristics, please refer to our previous
papers (Maremmani et al., 2007, 2008). We selected patients who
had requested medication to limit their craving for cocaine. We
studied patients who had taken prescribed ropinirole for almost
1month and had used cocaine, at least once, during the ropini-
role intake period. Patients were evaluated twice: at the beginning
of the ropinirole treatment we recorded the prescribed dose of
ropinirole and collected information in constructing a sociode-
mographic proﬁle, clinical history, and cocaine involvement for
each participant; at the end of the treatment period (lasting at least
1month) we went on to record the intensity of the rush blockade
and the self-reported reaction to it (whether the cocaine dose was
being increased or decreased, or was held at its usual level).
All subjects gave their oral informed consent to the anony-
mous use of the questionnaires for research purposes. The study
procedures were in accordance with the Helsinki Declaration of
1975.
SAMPLE
The sample consisted of 19 heroin-dependent patients. Table 1
reports main demographic and clinical characteristics of our
patients.
According to Cocaine Problem Severity Index (CPSI-RS) crite-
ria, 1 patient showed a recreational use of cocaine, 10 reported a
non-addictive form of abuse (moderate severity), and 8 reported a
markedly severe form of addiction that they judged to be treatable
in an outpatient setting.
The ropinirole dosages prescribed were 1.23± 0.4mg/daily.
INSTRUMENTS
Sociodemographic and clinical features were recorded using the
Drug Addiction History Rating Scale (DAH-RS; Maremmani and
Castrogiovanni, 1989), an instrument which is tailored to the pur-
pose of collecting clinical information in cases of heroin ab(use)
and dependence.
The DAH-RS is a multi-scale questionnaire assessing the fol-
lowing issues: somatic health, mental health, typology of abused
Table 1 | Demographic and clinical characteristics.
Age 31±6
Sex (males) 15 (78.9)
Marital status (single) 15 (78.9)
Education (<8 years) 11 (57.9)
Unemployed 3 (15.8)
Income (poor) 6 (31.6)
Living situation (in family) 15 (78.9)
Somatic comorbidity 14 (73.3)
Psychopathological impairment 18 (94.7)
Work major problems 10 (52.6)
Household major problems 12 (63.2)
Social and leisure major problems 8 (42.1)
Legal problems 5 (26.3)
Polyabusers 7 (36.8)
Age of onset of heroin dependence 21±3
Heroin dependence length (months) 90±51
Age of ﬁrst treatment for heroin 25±4
First treatment for heroin 6 (31.6)
substances, current and lifetime features of opiate use, treatment
history, social adjustment, and environmental factors. Nine fac-
tor scores are distinguished: physical problems, mental problems,
polysubstance abuse, previous treatment, combined treatments,
occupational level, family situation, sexual problems, socialization
and leisure time, and drug-related legal problems.
The dysfunctional uses of cocaine were evaluated by the CPSI-
RS (Rawson et al., 1989), in its Italian version. The CPSI-RS con-
sists of 18 items, each with 4 possible answers. Its total score ranges
from 0 to 84. The items investigate the degree of involvement with
cocaine, the pattern of consumption, drug-related environmental
features, and drug-induced somatic, mental and social impair-
ment. Four categories of cocaine use status are distinguished, as
follows: total score< 12= recreational use; total score in the 13–
25 range= non-addictive abuse or moderate severity; total score
in the 26–55 range= addiction treatable in an outpatient setting
or marked severity; total score in the 56–100 range= addiction
requiring hospitalization or extreme severity). Non-users fall into
a ﬁfth, zero-score, category.
The impact of ropinirole on the expected rush induced by
cocaine was evaluated by means of the “cocaine rush visual analog
scale” (CRVAS). The CRVAS consisted of two parallel columns,
representing the baseline expected intensity of cocaine rush (con-
trol column) and the level actually experiencedwhile on ropinirole,
in that order. The ﬁrst, control column corresponded to a subjec-
tive 100%, and subjects were asked to mark how intense their
cocaine rush had been, on average, while they were on ropinirole,
in the second column. TheCRAVwas administered to obtain a ret-
rospective assessment. Subjects had not been warned in advance
of a possible cocaine blockade.
The following additional parameters were recorded for each
patient: ropinirole dose, severity of cocaine use, intensity of rush
blockage, self-reported reaction to possible blockade during the
observation period.
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STATISTICAL ANALYSIS
We used a descriptive approach. Correlation between the percent-
age of maximum pre-ropinirole cocaine rush experienced and
sociodemographic and clinical variables were tested by multiple
regression analysis. Comparisons between time periods (intensity
of cocaine rush pre-ropinirole over a patient’s lifetime vs. inten-
sity during ropinirole treatment) were carried out usingWilcoxon
matched-pairs signed ranks test.
We used the statistical routines of SPSS package.
RESULTS
Table 2 shows various different features of the 19 patients belong-
ing to the sample. We reported age, gender, prescribed ropinirole
dose, severity of cocaine use, subjectively experienced cocaine rush
as a percentage of the pre-ropinirole effect, and the self-reported
post-ropinirole intake use of cocaine. Two patients (10.5%) expe-
rienced a complete blockade of cocaine rush and reported that,
during the observation period, they had reduced their use of
cocaine. Three patients (15.8%) felt cocaine as intensely as they
expected, with no blockade at all; of these, two reported that they
had reduced cocaine use during the observation period. Fourteen
patients (73.7%) experienced a partial blockade of cocaine rush;
of these, nine reported that they had reduced cocaine use during
the observation period.
Compared with their previous rush intensity 16 patients expe-
rienced lower intensity, 3 the same intensity, and none a higher
intensity (Wilcoxon pair test: z =−3.51; two-tailed P = 0.0004).
For details, see Table 3.
Overall, patients experienced 61.31± 32.1% of the maximum
intensity of the cocaine rush effect experienced in the past.
Using stepwise multiple regression analysis (criterion= per-
centage of maximum pre-ropinirole cocaine rush experienced),
no correlations were found between criterion and age, gen-
der, ropinirole dose, severity of cocaine use; no variables were
entered/removed during the analysis.
DISCUSSION
In a sample of stabilized heroin addicts with concurrent (ab)use
of cocaine, ropinirole proved to have a partial (in 73.7% of partici-
pating subjects) or complete (in 10.5% of these subjects) blockade
effect on the expected rush induced by cocaine. All the patients
who experienced a complete blockade effect (n = 2) reported that
their use of cocaine had fallen during the observation period. Of
the patients who experienced a partial blockade effect (n = 14)
a clear majority (n = 9) reported that their use of cocaine had
been reduced during the observation period. Lastly, two of the
three patients who felt cocaine to the same degree of intensity as
Table 3 | Percentage of cocaine rush blockade.
Percentage of maximum
cocaine-induced
subjective effects
N %
0 2 10.5
20 1 5.3
30 2 10.5
50 2 10.5
60 1 5.3
70 3 15.8
80 3 15.8
85 1 5.3
90 1 5.3
100 3 15.8
Table 2 | Synopsis.
ID Age Gender Intaked ropinirole
dose (mg)
Cocaine use
severity
Rush experienced
(as a %)
Cocaine use
1 44 Male 2,000 3 85 Not reduced
2 28 Male 1,000 3 70 Not reduced
3 31 Female 1,500 3 100 Reduced
4 31 Male 1,500 3 70 Not reduced
5 27 Male 1,500 3 100 Reduced
6 35 Male 1,500 1 70 Reduced
7 27 Male 2,000 2 100 Not reduced
8 31 Female 1,500 3 90 Reduced
9 30 Male 1,000 2 80 Reduced
10 29 Female 1,000 3 50 Reduced
11 34 Male 500 2 30 Not reduced
12 34 Male 2,000 2 30 Not reduced
13 37 Male 750 2 60 Reduced
14 33 Male 1,000 2 80 Reduced
15 35 Male 1,000 2 80 Reduced
16 19 Female 1,000 2 0 Reduced
17 27 Male 1,500 3 20 Reduced
18 32 Male 500 2 0 Reduced
19 20 Male 750 2 50 Reduced
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they had expected reported a reduction in cocaine use during the
observation period.
All the patients (except one) who requested cocaine anti-
craving therapy scored above theCPSI threshold for cocaine abuse,
so that the subjective judgment that they were in need of help
turned out to be consistent with an objective measurement of the
severity of their engagement with substance abuse.
Ropinirole does diminish the subjective intensity of the previ-
ously experienced cocaine rush, thus interferingwith the dynamics
of reward. This mechanism was probably fundamental in the two
patients who experienced a complete blockade of their cocaine
rush, by determining the subsequent self-reported reduction in
their cocaine use. Looking at this question from another angle,
it may be hypothesized that ropinirole’s dopamine-stimulating
action reasonably provides a certain degree of support to the
dopamine-mediated functions with a related anti-craving effects.
This second mechanism could come into play, together with the
ﬁrst one, in the patients who experienced a partial blockade effect
of their cocaine rush and reported that, during the observation
period, they had reduced their use of cocaine. Lastly, the hypothe-
sized anti-craving effect of ropinirole could at least partly explain
the self-reported reduction in cocaine use in two patients who
did not experience any blockade at all of cocaine rush. It should be
added that this study does not support the hypothesis that the suc-
cess or failure of an anti-reward approach depends on the severity
of cocaine abuse.
To the best of our knowledge the role of ropinirole in cocaine
dependence treatment has been the subject of very few investiga-
tions. In particular, only one pilot open-label trial has considered
the administration of ropinirole in cocaine-dependent patients
(Meini et al., 2008, 2011).
The modulation of reinforcing subjective cocaine effects, as
reported by our patients, is consistent with the study just cited
and supports several papers suggesting that psychostimulants
may play a role in the pharmacotherapy of cocaine depen-
dence (Castells et al., 2010). Other agents that support the
dopaminergic system, such as disulﬁram, have been tested in
cocaine dependence treatment (Pani et al., 2010). In addition,
ropinirole has been proposed as a possible therapeutic strat-
egy for the treatment of methamphetamine abuse (Hoefer et al.,
2006).
Nevertheless, it must be stressed that, on the therapeutic level,
the reported partial capacity of ropinirole to block cocaine sen-
sitivity proved to be insufﬁcient, in our patients, to achieve their
detachment from cocaine to any great degree. In fact, the “partial”
anti-reward effect seems to be only partly mirrored by the thera-
peutic response, as far as reduction in cocaine use is concerned.
In addition, the partial anti-reward coverage was unable to pre-
vent the exacerbation of cocaine use to overcome the ropinirole-
induced blockade. In other words, this anti-reward effect may pro-
mote ropinirole treatment discontinuation, presumably in order
to restore patients’ sensitivity to cocaine.
This phenomenon resembles that of the effects of buprenor-
phine on the mu-opioidergic system. On the other hand, in a
way similar to that found with buprenorphine, the low degree of
agonist action coupled with a signiﬁcant level of blockade may
turn out to be critical in patients whose metabolic system has
undergone major conditioning by substance intoxication (Dum
and Herz, 1981; Budd, 1983; Bickel et al., 1988; Walsh et al., 1995;
Barnett et al., 2001; Zuurmond et al., 2002; Virk et al., 2009).
LIMITATIONS
As limitations we must consider the low number of subjects and
the naturalistic design of the study. Besides, another limitation is
that the subjects included in the study were methadone treated
heroin addicts and not pure cocaine users. The presence of multi-
ple substance abuse is a common and peculiar condition that can
alter the interpretation of data.
CONCLUSION
In conclusion, this study, which suggests that ropinirole may exert
a partial blocking effect on cocaine rush, supports the view that
this medication could play a positive role in the pharmacotherapy
of cocaine dependence.
Randomized controlled trials are now needed to verify this
hypothesis.
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